viewOpen Orphan PLC

Open Orphan 'continuing to target rapid scale-up and profitability'

Proactive Research analyst Emma Ulker says Open Orphan (LON:ORPH) is continuing to target rapid scale-up and profitability in the dynamic European orphan and rare disease consulting sector via acquisitions and organic means.

The company’s Venn Life Sciences consulting arm has recently signed a thee-year preferred partnership agreement with leading European pharma company, Ipsen.

She adds that a new clinical-stage contract with Japan-based oncology and autoimmune disease specialist, Carna Biosciences, is further evidence of ORPH’s ability to extend Venn’s existing strong relationships within the industry.

Click here to read Emma Ulker's latest note on Open Orphan: Leveraging expertise and relationships for growth

Quick facts: Open Orphan PLC

Price: 15.59 GBX

Market: AIM
Market Cap: £92.53 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...



Open Orphan PLC: 'Rapidly scaling up and building out higher value, longer...

  Proactive Research analyst Emma Ulker says Open Orphan PLC (LON:ORPH) is a world leader in the testing of vaccines and anti-viral treatments through the use of human challenge study services. She says with its hVIVO subsidiary now integrated, it's leveraging its capabilities to the...

2 weeks, 5 days ago

2 min read